Ependymoma in Children

Status: draft · Last updated 2026-11-11 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • WHO 2021: classify by site and molecular group:
    • Supratentorial: ZFTA (formerly C11orf95/RELA) or YAP1.
    • Posterior fossa: PFA or PFB.
    • Spinal: including MYCN-amplified.
    • Also: myxopapillary ependymoma (now grade 2) and subependymoma .
  • PFA:
    • Infants and young children, laterally located, CIMP-positive.
    • Subtotal resection is dismal.
    • 1q gain (EFS 47% vs. 83%) and 6q loss (PFS 7%) mark high risk .
  • PFB:
    • Older patients; 5-year PFS about 90%.
    • Some may be cured with gross total resection alone .
  • Supratentorial:
    • YAP1 does better than ZFTA.
    • CDKN2A deletion in ZFTA–RELA is high risk .
  • Extent of resection is the dominant modifiable factor. Gross total resection cut the hazard of death about sixfold (HR 0.16) .
  • Adjuvant therapy:
    • Focal RT, 59.4 Gy, including under age 3 .
    • Maintenance chemotherapy gave no benefit in a randomized trial .
  • Metastasis at diagnosis:
    • About 2%, with poor outcome (5-year PFS 13–29%) .
    • Depends on molecular group: ZFTA–RELA did better .

Landmark papers

  • St. Jude conformal RT (Merchant et al., Lancet Oncol 2009): 153 children treated with conformal RT after surgery. 7-year EFS was 69.1% and OS 81.0%, and gross total resection independently improved OS (HR 0.16) .
  • ACNS0121 (Merchant et al., J Clin Oncol 2019): a COG trial. Infratentorial tumors with 1q gain had a 5-year EFS of 47.4% vs 82.8% without it .
  • ACNS0831 (Smith et al., Neuro Oncol 2026): a randomized trial (325 children). Maintenance chemotherapy after RT did not help: 5-year EFS 69.2% vs 63.7%, not significant .

Ependymoma is now classified by location plus molecular group, not by histologic grade alone. DNA methylation profiling identified nine molecular groups, three in each compartment: supratentorial, posterior fossa and spine. This molecular classification outperformed histopathology for predicting outcome . In children, the mainstays of treatment remain maximal safe resection and focal conformal radiotherapy .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:ependymoma_groups:f43c0a9aa6f80df1© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Midsagittal child neuraxis with ependymoma compartments: supratentorial (ZFTA or YAP1 fusion-positive), posterior fossa PFA and PFB in the fourth ventricle with lateral extension through the foramen of Luschka, spinal intramedullary ependymoma, and myxopapillary ependymoma at the conus and filumEPENDYMOMA: LOCATION AND MOLECULAR GROUP← anteriorSupratentorialZFTA fusion-positive (mostcommon; ZFTA::RELA) or YAP1fusion-positive (young children)Posterior fossa, PFAinfants and young children;laterally located; balancedgenome; worse prognosis(1q gain, 6q loss = higher risk)Posterior fossa, PFBolder children and adults;better prognosisSpinal ependymoma (NF2)spinal MYCN-amplified is adistinct WHO typeMyxopapillary ependymoma(CNS WHO grade 2)dashed: extension through theforamen of Luschka toward the CPAWHO 2021: ependymomas classified by location + molecular features.
Midsagittal schematic of the child neuraxis (anterior to the left) showing where ependymomas arise and their WHO 2021 molecular groups. Supratentorial: ZFTA fusion-positive or YAP1 fusion-positive. Posterior fossa: PFA (infants and young children, worse prognosis) and PFB (older children and adults, better prognosis). Spinal: intramedullary spinal ependymoma (NF2; spinal MYCN-amplified is a distinct type) and myxopapillary ependymoma of the conus and filum. Not to scale.

Classification (WHO 2021)

Infratentorial (posterior fossa) ependymoma

Supratentorial ependymoma

Prognosis with and without metastasis

Adjuvant therapy

Related topics

References

  1. Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015;27(5):728–743. doi:10.1016/j.ccell.2015.04.002. PMID 25965575. verified
  2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
  3. Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 2009;10(3):258–266. doi:10.1016/S1470-2045(08)70342-570342-5). PMID 19274783. verified
  4. Merchant TE, Bendel AE, Sabin ND, et al. Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma. J Clin Oncol 2019;37(12):974–983. doi:10.1200/JCO.18.01765. PMID 30811284. verified
  5. Smith AA, Onar-Thomas A, Lensing S, et al. Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: a report from the Children's Oncology Group. Neuro Oncol 2026;28(5):1286–1297. doi:10.1093/neuonc/noaf285. PMID 41423745. verified
  6. Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 2014;506(7489):451–455. doi:10.1038/nature13109. PMID 24553141. verified
  7. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011;20(2):143–157. doi:10.1016/j.ccr.2011.07.007. PMID 21840481. verified
  8. Ramaswamy V, Hielscher T, Mack SC, et al. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol 2016;34(21):2468–2477. doi:10.1200/JCO.2015.65.7825. PMID 27269943. verified
  9. Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014;506(7489):445–450. doi:10.1038/nature13108. PMID 24553142. verified
  10. Baroni LV, Sundaresan L, Heled A, et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol 2021;23(8):1360–1370. doi:10.1093/neuonc/noab034. PMID 33580238. verified
  11. Cavalli FMG, Hübner JM, Sharma T, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 2018;136(2):227–237. doi:10.1007/s00401-018-1888-x. PMID 30019219. verified
  12. Vallejo FA, Monsour MA, Fredricks NS, et al. Supratentorial ependymoma: a comprehensive review of molecular classification, management strategies, and clinical outcomes (Part II of pediatric ependymomas across compartments). J Neurooncol 2026;180(1). doi:10.1007/s11060-026-05818-7. PMID 42848093. verified
  13. von Hoff K, Obrecht-Sturm D, Ghasemi DR, et al. Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries. Neuro Oncol 2026;28(2):520–534. doi:10.1093/neuonc/noaf218. PMID 41026848. verified
  14. Benesch M, Mynarek M, Witt H, et al. Newly diagnosed metastatic intracranial ependymoma in children: frequency, molecular characteristics, treatment, and outcome in the prospective HIT series. Oncologist 2019;24(9):e921–e929. doi:10.1634/theoncologist.2018-0489. PMID 30850560. verified
  15. Zacharoulis S, Ji L, Pollack IF, et al. Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors. Pediatr Blood Cancer 2008;50(2):231–235. doi:10.1002/pbc.21276. PMID 17610266. verified

Verification (2026-11-11): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts. The WHO 2021 types, markers, the ZFTA renaming, grading and the methylation statements come from the full text of reference 2 (PMC8328013), read via a fetch agent. Reference 12 has no page range on PubMed. The full text of reference 1 could not be retrieved (blocked by a bot check), so its subgroup-level survival details are not quoted; supratentorial and posterior fossa outcomes come from references 7, 8, 12 and 13 instead.

Caveats: